Amneal Pharmaceuticals (AMRX) EBT (2017 - 2026)

Amneal Pharmaceuticals' EBT history runs 10 years deep, the most recent figure standing at $80.2 million for Q1 2026.

• In Q1 2026, EBT rose 113.88% year-over-year to $80.2 million; the TTM figure through Mar 2026 stood at $181.9 million (up 213.65% YoY), while the FY2025 annual figure was $139.2 million, up 353.05% from the prior year.
• EBT was $80.2 million for Q1 2026 at Amneal Pharmaceuticals, up from $55.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of $80.2 million in Q1 2026 to a low of -$232.7 million in Q2 2022.
• Historically, EBT has averaged -$7.3 million across 5 years, with a median of $2.2 million in 2022.
• Biggest YoY gain for EBT was 953.07% in 2023; the steepest drop was 990.28% in 2023.
• A 5-year view of EBT shows it stood at -$7.7 million in 2022, then plunged by 990.28% to -$83.5 million in 2023, then jumped by 81.65% to -$15.3 million in 2024, then jumped by 460.57% to $55.2 million in 2025, then surged by 45.15% to $80.2 million in 2026.
• The last three EBT figures came in at $80.2 million (Q1 2026), $55.2 million (Q4 2025), and -$5.2 million (Q3 2025), per Business Quant data.